XML 52 R38.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Marketable Debt and Equity Securities - Equity Securities Transactions (Details) $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2021 USD ($) shares | Sep. 30, 2021 USD ($) shares | Aug. 31, 2021 | Jul. 31, 2021 USD ($) shares | Jun. 30, 2021 USD ($) shares | Dec. 31, 2020 USD ($) shares | Oct. 31, 2017 USD ($) shares | Dec. 31, 2021 USD ($) shares | Dec. 31, 2020 USD ($) | Dec. 31, 2017 shares
Equity Securities |  |  |  |  |  |  |  |  |  |
Net gains recognized on equity securities | $ |  |  |  |  |  |  |  | $ 39,289 | $ 105 |
Impairment | $ |  |  |  |  |  |  |  | 762 |  |
Preferred Stock |  |  |  |  |  |  |  |  |  |
Equity Securities |  |  |  |  |  |  |  |  |  |
Equity Securities without Readily Determinable Fair Value | $ | $ 31,262 |  |  |  |  | $ 16,071 |  | $ 31,262 | $ 16,071 |
Astria/Catabasis | Common Stock |  |  |  |  |  |  |  |  |  |
Equity Securities |  |  |  |  |  |  |  |  |  |
Shares received in noncash transaction |  |  |  |  | 259,206 |  |  |  |  |
Shares issued upon conversion |  |  |  |  | 3,580,539 |  |  |  |  |
Reverse stock split ratio |  |  | 0.166 |  |  |  |  |  |  |
Number of shares |  |  |  |  |  |  |  | 3,839,745 |  |
Astria/Catabasis | Preferred Stock |  |  |  |  |  |  |  |  |  |
Equity Securities |  |  |  |  |  |  |  |  |  |
Shares received in noncash transaction |  |  |  | 347 | 3,928 |  |  |  |  |
Number of preferred stock converted (in shares) |  |  |  |  | 3,581 |  |  |  |  |
Equity Securities without Readily Determinable Fair Value | $ | $ 312 |  |  | $ 1,100 | $ 12,100 |  |  | $ 312 |  |
Impairment | $ |  |  |  |  |  |  |  | $ 800 |  |
Technology License Agreement | MiRagen/Viridian |  |  |  |  |  |  |  |  |  |
Equity Securities |  |  |  |  |  |  |  |  |  |
Shares received in noncash transaction | 394,737 |  |  |  |  | 322,407 |  |  |  |
Purchase amount of share options or equity in noncash transaction | $ | $ 7,500 |  |  |  |  | $ 6,000 |  |  |  |
Technology License Agreement | MiRagen/Viridian | Common Stock |  |  |  |  |  |  |  |  |  |
Equity Securities |  |  |  |  |  |  |  |  |  |
Shares received in noncash transaction | 394,737 |  |  |  |  | 322,407 |  |  |  |
Technology License Agreement | Astria/Catabasis | Common Stock |  |  |  |  |  |  |  |  |  |
Equity Securities |  |  |  |  |  |  |  |  |  |
Reverse stock split ratio |  |  | 0.166 |  |  |  |  |  |  |
License Agreement | INmune |  |  |  |  |  |  |  |  |  |
Equity Securities |  |  |  |  |  |  |  |  |  |
Shares received in noncash transaction |  |  |  |  |  |  | 1,585,000 |  |  |
Purchase amount of share options or equity in noncash transaction | $ |  |  |  |  |  |  | $ 10,000 |  |  |
Number of shares |  |  |  |  | 192,533 |  |  |  |  |
Cash consideration on sale of option | $ |  |  |  |  | $ 15,000 |  |  |  |  |
License Agreement | INmune | Common Stock |  |  |  |  |  |  |  |  |  |
Equity Securities |  |  |  |  |  |  |  |  |  |
Shares received in noncash transaction |  |  |  |  |  |  |  |  |  | 1,585,000
Additional equity interests (as a percentage) |  |  |  |  | 10.00% |  |  |  |  | 10.00%
Option to acquire shares |  |  |  |  |  |  | 108,000 |  |  | 108,000
Shares issued upon conversion |  |  |  |  | 192,533 |  |  |  |  |
Purchase amount of share options or equity in noncash transaction | $ |  | $ 800 |  |  |  |  |  |  |  |
Net gains recognized on equity securities | $ |  | $ 900 |  |  |  |  |  |  |  |
Number of shares |  | 108,000 |  |  |  |  |  | 1,885,533 |  |
Cash consideration on sale of option | $ |  |  |  |  | $ 15,000 |  |  |  |  |

X
- Definition The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586 + Details
Name: | us-gaap_ConversionOfStockSharesConverted1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586 + Details
Name: | us-gaap_ConversionOfStockSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 8A -URI http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562 + Details
Name: | us-gaap_ImpairmentOfInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash consideration received from sale of option. + References No definition available. + Details
Name: | xncr_CashConsiderationOnSaleOfOption
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of shares that can be received [noncash or part noncash] on exercise of option. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References No definition available. + Details
Name: | xncr_NonCashOrPartNonCashAcquisitionNonCashFinancialOrEquityInstrument
Namespace Prefix: | xncr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount shares or share options could be purchased for in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References No definition available. + Details
Name: | xncr_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationShareValue
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares received [noncash or part noncash] for consideration of a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References No definition available. + Details
Name: | xncr_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesReceived
Namespace Prefix: | xncr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of common equity shares acquired or held in association with a collaboration agreement. + References No definition available. + Details
Name: | xncr_NumberOfSharesAcquired
Namespace Prefix: | xncr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of additional equity interests available to be obtained in a license agreement. + References No definition available. + Details
Name: | xncr_PercentageOfAdditionalEquityInterests
Namespace Prefix: | xncr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_CatabasisPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_TechnologyLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_MiragenViridianMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_InmuneBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |